LOXL2 and neoplasm: Given the emerging importance of the tumor-promoting ability of αSMA–positive CAFs, which has been shown in breast, prostate, pancreatic, and skin cancer mouse models [22–24], the use of LOXL2 inhibitors to target both tumor angiogenesis and CAF activation offers a powerful approach for targeting developing primary breast tumors.